Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.

Daniell KM, Bardia A, Sun F, Roberts SA, Brunelle CL, Gillespie TC, Sayegh HE, Naoum GE, Juric D, Isakoff SJ, Fitzgerald DM, Taghian AG.

Breast Cancer Res Treat. 2019 Jun;175(3):649-658. doi: 10.1007/s10549-019-05206-y. Epub 2019 Mar 27.

PMID:
30919166
3.

Breast cancer-related lymphedema: women's experiences with an underestimated condition.

Thomas-MacLean R, Miedema B, Tatemichi SR.

Can Fam Physician. 2005 Feb;51:246-7.

4.

Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study.

Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC.

Ann Surg Oncol. 2017 Oct;24(10):2972-2980. doi: 10.1245/s10434-017-5960-x. Epub 2017 Aug 1.

5.

The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study.

Zou L, Liu FH, Shen PP, Hu Y, Liu XQ, Xu YY, Pen QL, Wang B, Zhu YQ, Tian Y.

Breast Cancer. 2018 May;25(3):309-314. doi: 10.1007/s12282-018-0830-3. Epub 2018 Feb 3.

PMID:
29397555
6.

Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation.

Shah C, Wilkinson JB, Baschnagel A, Ghilezan M, Riutta J, Dekhne N, Balaraman S, Mitchell C, Wallace M, Vicini F.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1095-100. doi: 10.1016/j.ijrobp.2011.09.058. Epub 2011 Nov 16.

PMID:
22099041
7.
8.

Arm lymphoedema in a cohort of breast cancer survivors 10 years after diagnosis.

Johansson K, Branje E.

Acta Oncol. 2010;49(2):166-73. doi: 10.3109/02841860903483676.

PMID:
20100154
9.

Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer - a long-term observation.

Rupp J, Hadamitzky C, Henkenberens C, Christiansen H, Steinmann D, Bruns F.

Radiat Oncol. 2019 Mar 7;14(1):39. doi: 10.1186/s13014-019-1243-y.

10.

Diagnostic Methods, Risk Factors, Prevention, and Management of Breast Cancer-Related Lymphedema: Past, Present, and Future Directions.

Sayegh HE, Asdourian MS, Swaroop MN, Brunelle CL, Skolny MN, Salama L, Taghian AG.

Curr Breast Cancer Rep. 2017 Jun;9(2):111-121. doi: 10.1007/s12609-017-0237-8. Epub 2017 May 3.

11.

The effect of providing information about lymphedema on the cognitive and symptom outcomes of breast cancer survivors.

Fu MR, Chen CM, Haber J, Guth AA, Axelrod D.

Ann Surg Oncol. 2010 Jul;17(7):1847-53. doi: 10.1245/s10434-010-0941-3. Epub 2010 Feb 6.

PMID:
20140528
12.

Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up.

Invernizzi M, Corti C, Lopez G, Michelotti A, Despini L, Gambini D, Lorenzini D, Guerini-Rocco E, Maggi S, Noale M, Fusco N.

BMC Cancer. 2018 Sep 29;18(1):935. doi: 10.1186/s12885-018-4851-2.

13.

Lymph node status and breast cancer-related lymphedema.

Purushotham AD, Bennett Britton TM, Klevesath MB, Chou P, Agbaje OF, Duffy SW.

Ann Surg. 2007 Jul;246(1):42-5.

14.

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M.

Cancer Treat Rev. 2018 Jan;62:123-132. doi: 10.1016/j.ctrv.2017.09.009. Epub 2017 Nov 3. Review.

PMID:
29108713
15.

Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial.

Schmitz KH, Ahmed RL, Troxel AB, Cheville A, Lewis-Grant L, Smith R, Bryan CJ, Williams-Smith CT, Chittams J.

JAMA. 2010 Dec 22;304(24):2699-705. doi: 10.1001/jama.2010.1837. Epub 2010 Dec 8.

PMID:
21148134
16.

Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab.

Invernizzi M, Michelotti A, Noale M, Lopez G, Runza L, Giroda M, Despini L, Blundo C, Maggi S, Gambini D, Fusco N.

J Clin Med. 2019 Jan 24;8(2). pii: E138. doi: 10.3390/jcm8020138.

17.

Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments.

Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG.

Gland Surg. 2018 Aug;7(4):379-403. doi: 10.21037/gs.2017.11.04. Review.

18.

Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.

Beith J, Burslem K, Bell R, Woodward N, McCarthy N, De Boer R, Loi S, Redfern A.

Asia Pac J Clin Oncol. 2016 Mar;12 Suppl 1:3-18. doi: 10.1111/ajco.12491. Review.

PMID:
27001208
19.

Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.

Zhang X, Li XR, Zhang J.

Curr Cancer Drug Targets. 2013 Feb;13(2):175-87. Review.

PMID:
23215724
20.

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.

Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A, Wong KK.

Ther Adv Med Oncol. 2018 Nov 9;10:1758835918808509. doi: 10.1177/1758835918808509. eCollection 2018. Review.

Supplemental Content

Support Center